RALEIGH, N.C., Aug. 16 /PRNewswire/ -- PRA International, a leading Clinical Research Organization, will host an audio conference on strategies for successful cardiovascular (CV) drug development on 24 August 2010 at 11:30 am (EDT). Dr. Michael Kirchengast, Vice President and Head of PRA's Scientific Affairs unit, will be the presenter.
Dr. Kirchengast will discuss ways to prevent some of the expensive failures that pharmaceutical companies experience during late-stage CV drug development. The conference will review predictive pre-clinical models, innovative proof-of-concept designs in Phase IIa, cooperation among sponsors and regulatory agencies, and simpler protocols with similar endpoints throughout Phases II and III.
PRA's therapeutic expert in CV disease, Dr. Kirchengast has 30 years of experience in CV research and development, including interactions with multiple authorities. His wide range of development experience encompasses antiarrhythmics, antithrombotics, antihypertensives, antihyperlipidemics, heart failure therapeutics, and vascularly active and cardioprotective drugs.
PRA's Scientific Affairs group consists of strategic drug development professionals with expertise in medical informatics and investigator relations as well as therapeutic expertise in cardiovascular, oncology/hematology, infectious diseases, neurosciences, pediatrics, and respiratory medicine. The group combines in-house scientific expertise with hands-on pharmaceutical industry experience, guiding the development of drugs and biologics from the late preclinical phase to the marketing stage across PRA's core therapeutic areas.
About PRA International